Mesoblast (MEOBF) Net Margin (2014 - 2023)
Mesoblast's (MEOBF) quarterly Net Margin came in at 1290.67% in Q2 2023, down 22379.0% year-over-year from N/an in Q2 2022, and down 34.55% quarter-over-quarter from 959.26% in Q1 2023.
Analysis
Mesoblast (MEOBF) Net Margin (2014 - 2023) Analysis & Trends
Mesoblast has disclosed Net Margin across 10 years of filings, most recently posting 1290.67% for Q2 2023.
- In Q2 2023, Net Margin fell 22379.0% year-over-year to 1290.67%; the TTM figure through Jun 2023 stood at 1129.22% (down 31011.0% YoY), while the FY2026 annual figure was 47.82%, up 55788.0% from the prior year.
- Net Margin came in at 1290.67% for Q2 2023 at Mesoblast, down from 959.26% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 32.17% in Q3 2019 to a low of 1999.2% in Q1 2019.
- Average Net Margin over 5 years is 1054.92%, with a median of 1123.35% recorded in 2022.
- The largest YoY upside for Net Margin was 185509 bps in 2020 against a maximum downside of 184860 bps in 2020.
- Over 5 years, Net Margin stood at 832.88% in 2019, then slumped by 38 bps to 1146.45% in 2020, then surged by 36 bps to 733.74% in 2021, then slumped by 56 bps to 1147.42% in 2022, then declined by 12 bps to 1290.67% in 2023.
- Per Business Quant data, the three most recent Net Margin figures were 1290.67% in Q2 2023, 959.26% in Q1 2023, and 1147.42% in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.42 Bn | 112.79 Mn | 45.94% |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | -895.73% |
| 3 | Iovance Biotherapeutics | 3.78 Bn | 3.49 Bn | 55.72 Mn | -47.62% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 20.08% |
| 5 | uniQure | 3.06 Bn | 3.06 Bn | 5.49 Mn | -1,387.76% |
| 6 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | -25,036.33% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.35 Bn | 1.55 Bn | 251.87 Mn | -1.22% |
| 9 | Vericel | 2.00 Bn | 1.83 Bn | 56.40 Mn | 2.88% |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -1,290.67% |
| Mar 31, 2023 | -959.26% |
| Dec 31, 2022 | -1,147.42% |
| Sep 30, 2022 | -1,123.35% |
| Jun 30, 2022 | -1,066.88% |
| Mar 31, 2022 | -1,059.27% |
| Dec 31, 2021 | -733.74% |
| Sep 30, 2021 | -630.08% |
| Jun 30, 2021 | -1,126.08% |
| Mar 31, 2021 | -1,384.60% |
| Dec 31, 2020 | -1,146.45% |
| Sep 30, 2020 | -1,880.77% |
| Mar 31, 2020 | -144.11% |
| Dec 31, 2019 | -832.88% |
| Sep 30, 2019 | -32.17% |
| Jun 30, 2019 | -1,376.72% |
| Mar 31, 2019 | -1,999.20% |
| Dec 31, 2018 | -1,315.72% |
| Sep 30, 2018 | -167.55% |
| Jun 30, 2018 | -1,225.53% |